Efficacy of pentosan polysulfate treatment in patients with interstitial cystitis/bladder pain syndrome
Yükleniyor...
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Pol Scientific
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objectives: Pentosan Polysulfate (PPS) is the only oral treatment for interstitial cystitis (IC)-bladder pain syndrome (BPS) approved by the World Health Organization. Self-evaluation scales can provide more objective results on pre- and post-treatment satisfaction. The aim of this study was to investigate the effect of pentosan polysulfate treatment on symptoms in IC-BPS patients. Methods: This study included 37 adult male and female patients with IC-BPS who reported pain, urinary urgency, polyurea, and nocturia without urinary tract infection for a minimum of six months prior to the study and were taking 300 mg/day oral pentosan polysulfate. Pre- and post-treatment symptoms, Interstitial Cystitis Symptom Index (ICSI) Scores, quality of life (QoL) scores (1-4), and satisfaction conditions were examined. Results: Following the application of inclusion and exclusion criteria, mean age of 37 suitable patients was 46.0±11.9 years and 27% (10 individuals) of the patients were male. Pre-treatment, ICSI scores, and measures of satisfaction degree and QoL increased significantly after the treatment (p<0.001). Adverse reaction was detected in two patients (5.4%) among the patients treated with pentosan polysulfate. Conclusions: Oral pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome treatment could achieve recovery in symptoms, increase Interstitial Cystitis Symptom Index score and improve quality of life and patient satisfaction.
Açıklama
Anahtar Kelimeler
Bladder pain syndrome, Efficacy, Interstitial cystitis, Pentosan polysulfate, Treatment
Kaynak
Bladder (San Franc)
WoS Q Değeri
Scopus Q Değeri
Cilt
10
Sayı
Künye
Arıkan MG Çakıroğlu B. Efficacy of Pentosan Polysulfate Treatment in Patients with Interstitial Cystitis/
Bladder Pain Syndrome. Bladder 2023;10:e21200007. DOI: 10.14440/bladder.2023.866
